

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

**VOLUNTARY ANNOUNCEMENT
INCLUSION AS A CONSTITUENT OF
HANG SENG FAMILY OF INDEXES AND MSCI INDEXES**

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that the Company has been selected and will be included as a constituent stock of the following indexes by the Hang Seng Indexes Company Limited with effect from March 4, 2024:

1. Hang Seng Composite Index
2. Hang Seng Composite Industry Index – Healthcare
3. Hang Seng Composite MidCap & SmallCap Index
4. Hang Seng Composite SmallCap Index
5. Hang Seng Small Cap (Investable) Index
6. Hang Seng Healthcare Index
7. Hang Seng Innovative Drug Index
8. Hang Seng Stock Connect Hong Kong Index
9. Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
10. Hang Seng Stock Connect Hong Kong SmallCap Index
11. Hang Seng SCHK Mainland China Companies Index
12. Hang Seng SCHK Innovative Drug Select Index
13. Hang Seng SCHK Pharmaceuticals & Biotechnology (Investable) Index
14. Hang Seng SCHK Innovative Drug Index

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalisation of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited, which can be used as a basis for index funds, mutual funds as well as performance benchmarks.

The Company was earlier included as a constituent stock of the MSCI Global Small Cap Index and MSCI China All Shares Small Cap Index with effect as of the market close of November 30, 2023. These indexes are compiled by MSCI Inc., and are designed to measure the performance of the small-cap segment of the market and widely recognized by the international financial community as benchmarks for global institutional investors seeking to optimize their investment portfolios.

The Board is of the view that the Company's inclusion as a constituent of these indexes reflects the capital market's strong recognition of the Group's business performance and growth outlook. The Board believes that such inclusion will facilitate the expansion of the Company's shareholder base, help increase the trading liquidity of the shares of the Company, and further enhance the reputation and brand awareness of the Group.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, February 19, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.